Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 18/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2107730 | 0.88 | HDAC1 (0.69) | HDAC1HDAC2 | |
| SCHEMBL2108848 | 0.87 | HDAC1 (0.76) | HDAC1HDAC3HDAC2 | |
| SCHEMBL2108446 | 0.77 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL1689303 | 0.75 | HDAC1 (0.69) | HDAC1HDAC3HDAC2HDAC8HDAC6 | |
| SCHEMBL1689263 | 0.74 | HDAC1 (0.77) | HDAC1HDAC3HDAC2 | |
| SCHEMBL2107833 | 0.74 | HDAC1 (0.64) | HDAC1HDAC3HDAC2 | |
| SCHEMBL13202901 | 0.73 | HDAC1 (0.78) | HDAC1KMT2AHDAC3HDAC2HDAC8 | |
| SCHEMBL18653508 | 0.73 | HDAC1 (0.76) | HDAC1HDAC3HDAC2 | |
| SCHEMBL14853314 | 0.72 | HDAC1 (0.61) | HDAC1KMT2A | |
| SCHEMBL11911355 | 0.72 | MAPT (0.65) | HDAC1KMT2AHDAC3HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158825-B2 | Modified malonate derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100160327-A1 | Modified Malonate Derivatives | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160327-A1 | Modified Malonate Derivatives | ME2, ME3, ME1 | HDAC1 6/4885KMT2A 132/4885HDAC3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.